ROSEMARIE SCHMANDT to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications ROSEMARIE SCHMANDT has written about Xenograft Model Antitumor Assays.
Connection Strength
0.130
-
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
Score: 0.047
-
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020 03 16; 37(3):371-386.e12.
Score: 0.025
-
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013 Dec; 12(12):2847-56.
Score: 0.016
-
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.
Score: 0.012
-
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
Score: 0.012
-
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.
Score: 0.010
-
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 01; 65(15):6910-8.
Score: 0.009